First generic development of new antithrombotic drug, ‘Brilinta,’ has begun

Movements to develop the first generic of the AstraZeneca’s next-generation antithrombotic drug, Brilinta(generic name: ticagrelor), have been observed.

On the 14^th, the Ministry of Food and Drug Safety approved bioequivalence tests of ticagrelor 90mg applied by Binex, a biopharmaceutical venture.

Brilinta is a drug evaluated a next-generation antithrombotic treatment followed by aspirin and ...